Literature DB >> 1396897

Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome--a report of two cases.

R Rossi1, U Helmchen, G Schellong.   

Abstract

Two patients developed renal Fanconi syndrome (RFS) after intensive long-term chemotherapy for metastatic Ewing sarcoma and disseminated neuroblastoma. Whereas RFS was diagnosed in patient 1 before he developed osteomalacia, patient 2 experienced severe rickets and growth retardation. Renal function studies revealed slight glomerular impairment and severe tubular defects leading to increased excretion of glucose, amino acids, inorganic phosphate and low molecular weight proteins, indicating proximal tubular damage. Patient 2 additionally showed distal tubular dysfunction with acidosis and diminished concentrating capacity. Renal biopsy in patient 1 revealed marked proximal tubular defects without interstitial lymphocytic infiltration. In both patients renal damage could most likely be ascribed to previous ifosfamide (IFOS) therapy. Our patients showed no improvement in renal function after cessation of IFOS treatment, indicating a poor prognosis of once established RFS after IFOS therapy. Measurement of tubular reabsorption capacities provides exact information on the extent of tubular toxicity induced by IFOS and may be used to monitor IFOS treated patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396897     DOI: 10.1007/bf02113264

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Acute ifosfamide-induced tubular toxicity.

Authors:  D Heney; I J Lewis; C C Bailey
Journal:  Lancet       Date:  1989-07-08       Impact factor: 79.321

Review 2.  Aminoaciduria and hyperaminoaciduria in childhood.

Authors:  J Brodehl; H Bickel
Journal:  Clin Nephrol       Date:  1973 May-Jun       Impact factor: 0.975

Review 3.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Nephrotoxicity associated with ifosfamide.

Authors:  J Smeitink; M Verreussel; C Schröder; R Lippens
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

5.  Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

Authors:  M P Goren; R K Wright; C B Pratt; M E Horowitz; R K Dodge; M J Viar; E H Kovnar
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

6.  DDAVP test for assessment of renal concentrating capacity in infants and children.

Authors:  L Monnens; Y Smulders; H van Lier; T de Boo
Journal:  Nephron       Date:  1981       Impact factor: 2.847

Review 7.  Renal glucosuria.

Authors:  J Brodehl; B S Oemar; P F Hoyer
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

8.  Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling.

Authors:  H Stark; B Eisenstein; M Tieder; A Rachmel; G Alpert
Journal:  Nephron       Date:  1986       Impact factor: 2.847

9.  Postnatal development of tubular phosphate reabsorption.

Authors:  J Brodehl; K Gellissen; H P Weber
Journal:  Clin Nephrol       Date:  1982-04       Impact factor: 0.975

10.  Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

Authors:  M P Goren; R K Wright; M E Horowitz; C B Pratt
Journal:  Cancer Treat Rep       Date:  1987-02
View more
  2 in total

1.  Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide.

Authors:  J de Schepper; S Hachimi-Idrissi; O Louis; R Maurus; J Otten
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

2.  The influence of ifosfamide scheduling on acute nephrotoxicity in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.